VOQUEZNA DUAL PAK Drug Patent Profile

When do Voquezna Dual Pak patents expire, and when can generic versions of Voquezna Dual Pak launch?

Voquezna Dual Pak is a drug marketed by Phathom and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and three patent family members in forty-three countries.

The generic ingredient in VOQUEZNA DUAL PAK is amoxicillin; vonoprazan fumarate. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; vonoprazan fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Voquezna Dual Pak

Voquezna Dual Pak was eligible for patent challenges on May 3, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 3, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VOQUEZNA DUAL PAK

International Patents:	103
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Drug Prices:	Drug price information for VOQUEZNA DUAL PAK
What excipients (inactive ingredients) are in VOQUEZNA DUAL PAK?	VOQUEZNA DUAL PAK excipients list
DailyMed Link:	VOQUEZNA DUAL PAK at DailyMed

See drug prices for VOQUEZNA DUAL PAK

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VOQUEZNA DUAL PAK

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

215153

Dosage:

CAPSULE, TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VOQUEZNA DUAL PAK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1

See all VOQUEZNA DUAL PAK clinical trials

US Patents and Regulatory Information for VOQUEZNA DUAL PAK

VOQUEZNA DUAL PAK is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Phathom	VOQUEZNA DUAL PAK	amoxicillin; vonoprazan fumarate	CAPSULE, TABLET;ORAL	215153-001	May 3, 2022		RX	Yes	Yes	9,186,411		Y
Phathom	VOQUEZNA DUAL PAK	amoxicillin; vonoprazan fumarate	CAPSULE, TABLET;ORAL	215153-001	May 3, 2022		RX	Yes	Yes
Phathom	VOQUEZNA DUAL PAK	amoxicillin; vonoprazan fumarate	CAPSULE, TABLET;ORAL	215153-001	May 3, 2022		RX	Yes	Yes	7,977,488			Y
Phathom	VOQUEZNA DUAL PAK	amoxicillin; vonoprazan fumarate	CAPSULE, TABLET;ORAL	215153-001	May 3, 2022		RX	Yes	Yes

International Patents for VOQUEZNA DUAL PAK

When does loss-of-exclusivity occur for VOQUEZNA DUAL PAK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Japan

Malaysia

Mexico

Morocco

New Zealand

Peru

Singapore

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VOQUEZNA DUAL PAK around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	055144
Argentina	107852
Austria	E504567
Australia	2006285641
Brazil	122017028096
Brazil	PI0615111

VOQUEZNA DUAL PAK Market Dynamics, Financial Trajectory, Patents and Generic Risk

Last updated: August 4, 2026

VOQUEZNA DUAL PAK is Phathom Pharmaceuticals' U.S. branded regimen of vonoprazan fumarate and amoxicillin for the eradication of Helicobacter pylori infection in adults. The product competes against established antibiotic combinations, Talicia, Pylera and generic proton-pump-inhibitor regimens. Its commercial value depends on physician adoption of potassium-competitive acid blockers, reimbursement, H. pylori testing rates and the ability to defend branded combination-kit economics against inexpensive generic components.

Phathom's larger growth opportunity is VOQUEZNA tablets for erosive gastroesophageal reflux disease and associated heartburn, approved in 2023. The Dual Pak is strategically important but is unlikely to remain the company's primary revenue driver if the GERD launch scales.

What is VOQUEZNA DUAL PAK and what is it approved to treat?

VOQUEZNA DUAL PAK combines:

Component	Dose in the approved regimen	Role
Vonoprazan fumarate	20 mg twice daily	Potassium-competitive acid blocker
Amoxicillin	1,000 mg twice daily	Antibiotic

The treatment is administered for 14 consecutive days. The FDA approved VOQUEZNA DUAL PAK on May 3, 2022, for the treatment of H. pylori infection in adults. The same approval covered VOQUEZNA TRIPLE PAK, which adds clarithromycin to vonoprazan and amoxicillin.[1]

Vonoprazan suppresses gastric acid through competitive and reversible inhibition of the gastric H+/K+-ATPase. Its pharmacologic profile differs from proton-pump inhibitors because it does not require acid activation and can produce rapid, sustained acid suppression. That characteristic supports antibiotic activity in the stomach and is central to the product's positioning in H. pylori eradication.

How does VOQUEZNA DUAL PAK compare with competing H. pylori treatments?

VOQUEZNA DUAL PAK competes on regimen simplicity, acid suppression and clinical performance rather than on lowest acquisition cost.

Product or regimen	Active ingredients	Commercial position	Main competitive issue
VOQUEZNA DUAL PAK	Vonoprazan and amoxicillin	Branded dual therapy	Higher price than generic component regimens
VOQUEZNA TRIPLE PAK	Vonoprazan, amoxicillin and clarithromycin	Branded triple therapy	Clarithromycin resistance limits use in some patients
Talicia	Rifabutin, amoxicillin and omeprazole	Branded H. pylori therapy	Direct branded competitor
Pylera	Bismuth, metronidazole and tetracycline	Established branded combination	High pill burden and tolerability concerns
Generic bismuth quadruple therapy	Bismuth, metronidazole, tetracycline and acid suppression	Low-cost standard option	Complex administration
Generic triple therapy	Clarithromycin, amoxicillin and PPI	Broadly available	Antibiotic resistance and lower differentiation

The Dual Pak's practical advantage is the absence of clarithromycin. That reduces exposure to clarithromycin resistance, which has weakened traditional triple therapy. The regimen still requires twice-daily administration of two separate drug types and does not eliminate antibiotic-related adverse events.

The key commercial disadvantage is that amoxicillin is generic and inexpensive. Phathom must persuade prescribers, payers and specialty pharmacies that branded packaging and vonoprazan-based acid suppression justify a premium over generic regimens.

What is the FDA regulatory status of VOQUEZNA DUAL PAK?

VOQUEZNA DUAL PAK is FDA-approved for H. pylori eradication in adults. It is a branded combination package, not a new fixed-dose tablet containing both active ingredients. The FDA labeling includes warnings associated with hypersensitivity, antibiotic-associated diarrhea, Clostridioides difficile infection and adverse reactions linked to vonoprazan and amoxicillin.[1]

Phathom later received FDA approval for VOQUEZNA tablets in erosive GERD and for relief of heartburn associated with erosive GERD. The 2023 GERD approval materially expanded the commercial addressable market beyond H. pylori treatment.[2]

Does VOQUEZNA DUAL PAK have FDA exclusivity?

The product's principal commercial protection is patent-based rather than biologic exclusivity. H. pylori treatment is a small, episodic market, so regulatory exclusivity alone would not support a large long-term revenue stream.

The relevant exclusivity factors are:

• The 2022 approval established the branded H. pylori indication.
• The 2023 VOQUEZNA GERD approval created a broader product platform.
• Vonoprazan is a small molecule, so biosimilar exclusivity does not apply.
• Generic applicants may pursue an ANDA and challenge listed patents through Paragraph IV certifications.
• The combination package includes an established generic antibiotic, increasing substitution pressure.

What patents protect VOQUEZNA DUAL PAK?

The patent estate is expected to cover multiple layers rather than a single patent directed only to the retail package.

Vonoprazan compound and salt patents

The foundational protection relates to vonoprazan and pharmaceutically acceptable salts, including vonoprazan fumarate. These rights originated with Takeda and were licensed to Phathom for North American commercialization.[3]

Formulation and dosage-form patents

Additional protection can cover:

• Oral vonoprazan formulations
• Tablet compositions
• Stability and manufacturing characteristics
• Dosage strengths
• Combination regimens containing vonoprazan and antibiotics

Method-of-use patents

The commercially important use claims include treatment of H. pylori infection, acid-related diseases and erosive GERD. Method-of-use claims can create separate litigation exposure even if a generic applicant avoids a composition claim.

Combination and packaging protection

VOQUEZNA DUAL PAK is a kit containing separately packaged vonoprazan and amoxicillin. Patent protection may therefore apply to the combination regimen, dosing schedule, packaging configuration or therapeutic use. Packaging protection alone is generally weaker than a composition patent because an ANDA applicant may attempt to market the active ingredients separately or design around kit claims.

Current Orange Book listings, patent numbers and expiration dates should be evaluated at the product-specific level because listings can change through patent delisting, corrections, pediatric extensions and litigation outcomes. The core business risk is that a generic applicant may challenge vonoprazan patents while continuing to source amoxicillin as a generic ingredient.[4]

When does VOQUEZNA DUAL PAK lose exclusivity?

There is no single commercial loss-of-exclusivity date for the Dual Pak. The relevant date is the earliest date on which a legally authorized generic or other competitor can enter without being blocked by an enforceable patent or settlement restriction.

The principal timing variables are:

Exclusivity variable	Effect on entry
Orange Book-listed vonoprazan patents	Can support Paragraph IV litigation
Patent-term adjustment or extension	May move the effective expiry date
Method-of-use claims	Can block labeled use but may be subject to skinny-label strategies
Kit or combination claims	May be designed around
Paragraph IV settlement	Can establish an agreed entry date before patent expiry
Regulatory review	A successful ANDA still requires FDA approval
Commercial launch economics	Small H. pylori volume may delay entry even after approval

The product's practical exclusivity may be shorter than the full patent term if generic vonoprazan becomes available for other indications, if payers favor separate generic components or if a generic entrant avoids the branded kit.

Which companies are challenging VOQUEZNA DUAL PAK?

No major publicly established generic launch has displaced VOQUEZNA DUAL PAK in the U.S. market through the latest company-reported period covered here. Potential challengers include large generic manufacturers with experience in ANDA litigation and smaller specialty-generic companies that can commercialize vonoprazan or a therapeutically equivalent regimen.

The most likely challenge formats are:

1. An ANDA for vonoprazan tablets.
2. A Paragraph IV challenge to listed vonoprazan patents.
3. A separate generic amoxicillin product used alongside generic vonoprazan.
4. A competing H. pylori kit that avoids the VOQUEZNA trade dress and package configuration.
5. A skinny-label product that excludes patented GERD indications while retaining an unpatented or differently protected H. pylori use.

A direct generic substitute for the entire Dual Pak would face packaging and labeling issues. A generic vonoprazan tablet paired with generic amoxicillin could create greater price pressure without replicating the branded kit.

What patent litigation affects VOQUEZNA DUAL PAK?

The major litigation risk is future ANDA litigation under the Hatch-Waxman Act. A Paragraph IV notice would require Phathom or its licensed patent holders to decide whether to sue within the statutory period. A timely suit can trigger a 30-month stay of FDA approval for the challenged ANDA, subject to statutory exceptions and court decisions.[5]

The litigation profile is likely to center on:

• Vonoprazan composition and salt claims
• Tablet formulation claims
• H. pylori treatment claims
• Combination therapy claims
• Patent validity and obviousness
• Written description and enablement
• Design-around arguments involving separate packaging or dosing

No biosimilar litigation pathway applies because VOQUEZNA contains a small-molecule active ingredient. That reduces the complexity associated with biologic interchangeability but leaves conventional ANDA and patent litigation risk intact.

What is the financial trajectory of VOQUEZNA DUAL PAK and Phathom Pharmaceuticals?

Phathom's financial trajectory has two phases.

Phase one: H. pylori commercialization

VOQUEZNA DUAL PAK and TRIPLE PAK generated the company's first commercial revenue after the 2022 launch. Phathom reported approximately $75.6 million of total product revenue in 2023, reflecting continued uptake of the H. pylori products and the beginning of the broader VOQUEZNA franchise.[6]

The H. pylori business has favorable commercial characteristics:

• A clear treatment indication
• A differentiated acid-suppression mechanism
• Potential use after failure of conventional therapy
• Specialty-pharmacy distribution
• Limited direct competition from other potassium-competitive acid blockers in the U.S.

Its limitations are equally important:

• H. pylori treatment is episodic rather than chronic.
• The treated population is smaller than the GERD population.
• Amoxicillin remains widely available at generic prices.
• Gastroenterologists and primary-care physicians have established low-cost alternatives.
• Payer restrictions can limit branded prescribing.

Phase two: GERD expansion

The 2023 GERD approval broadened VOQUEZNA from an H. pylori regimen into a chronic acid-related disease franchise. Chronic GERD treatment has a much larger patient population and creates prescription refill potential. Phathom launched VOQUEZNA for erosive GERD in late 2023, making GERD the principal source of potential revenue acceleration.[2,6]

The financial model therefore depends less on Dual Pak unit growth than on whether VOQUEZNA tablets can secure a meaningful share of the branded GERD market. Commercial investment in sales representatives, payer access and direct-to-consumer promotion increases near-term operating expenses but is necessary to reach the larger indication.

Financial driver	Impact on trajectory
H. pylori diagnosis and treatment volume	Supports base revenue
GERD prescription growth	Main upside driver
Gross-to-net deductions	Reduces reported product revenue
Sales-force expansion	Raises near-term cash burn
Payer coverage	Determines prescription conversion
Patent durability	Protects price and market share
Generic vonoprazan entry	Creates the largest long-term downside
Takeda royalty and licensing obligations	Reduce net economics

Phathom remains dependent on VOQUEZNA because it does not have a diversified marketed-product portfolio comparable with larger pharmaceutical companies. That concentration creates high operating leverage: successful GERD uptake can improve revenue faster than expenses, while weak uptake can prolong losses and financing needs.

How much revenue exposure does VOQUEZNA DUAL PAK represent?

Dual Pak revenue is strategically meaningful but should not be treated as the full value of the VOQUEZNA franchise. The product is one part of a portfolio that includes TRIPLE PAK and VOQUEZNA tablets.

The commercial mix is expected to shift toward tablets because:

• GERD is a larger market than H. pylori treatment.
• Erosive GERD can generate repeat prescriptions.
• The tablets are not tied to antibiotic use.
• Vonoprazan can be positioned against PPIs and other acid-suppression products.
• A broader indication supports payer contracting and physician familiarity.

Dual Pak remains valuable as an entry point for vonoprazan adoption. Physicians who use it for H. pylori may be more willing to prescribe VOQUEZNA tablets for GERD, but that cross-indication effect is difficult to quantify.

How strong is the VOQUEZNA patent estate?

The estate has moderate-to-strong strategic value because vonoprazan is differentiated from PPIs and has multiple potential claim categories. Its strength depends on the enforceability and remaining term of the specific U.S. patents, not on the number of patents alone.

Strengths include:

• Licensed access to an established vonoprazan technology platform
• Multiple possible patent layers
• A clinically differentiated mechanism
• Combination and method-of-use opportunities
• Commercial expansion into GERD

Weaknesses include:

• Small-molecule ANDA exposure
• Generic availability of amoxicillin
• Potential design-around of the kit
• Method-of-use claim limitations
• Possible payer preference for low-cost alternatives
• Dependence on one primary active pharmaceutical ingredient

The strongest protection is likely to come from enforceable composition, formulation and dosage claims. The weakest protection is likely to come from packaging or narrow regimen claims that an ANDA sponsor can avoid.

What licensing deals support VOQUEZNA commercialization?

Phathom licensed North American rights to vonoprazan from Takeda. The agreement gave Phathom development and commercialization rights while preserving Takeda's economic participation through upfront payments, milestone obligations and royalties.[3]

The deal reduces Phathom's discovery risk because the active ingredient had already been developed and commercialized in other markets. It also creates continuing obligations that reduce gross-to-net profitability and increase the importance of achieving sufficient scale.

Geographic rights are important. Phathom's commercial opportunity is concentrated in North America, while Takeda retains rights in other regions. U.S. performance therefore drives Phathom's value more directly than it would for a multinational company with global commercialization rights.

What generic launch scenarios exist for VOQUEZNA DUAL PAK?

Three scenarios are commercially plausible.

Delayed generic entry

Phathom defends its patent estate successfully or reaches a settlement that delays entry until late in the patent term. Dual Pak retains premium pricing, although payer pressure remains.

Product-specific generic entry

A company launches generic vonoprazan or a competing H. pylori kit while the branded product remains available. Price erosion is significant, but physician familiarity and branded packaging preserve some share.

Rapid component substitution

Payers encourage physicians to prescribe separate generic amoxicillin with another acid-suppression product. This outcome would pressure Dual Pak before a direct generic kit becomes available.

The third scenario is the most immediate commercial risk because it does not require a generic company to reproduce the entire branded package.

Key Takeaways

• VOQUEZNA DUAL PAK is FDA-approved for 14-day H. pylori eradication in adults.
• Its active ingredients are vonoprazan fumarate and generic amoxicillin.
• The product competes against Talicia, Pylera and low-cost generic regimens.
• Phathom's larger growth opportunity is VOQUEZNA tablets for erosive GERD.
• The product has no biosimilar risk, but it has conventional small-molecule ANDA and Paragraph IV exposure.
• Patent value depends on composition, formulation and method-of-use claims more than on packaging protection.
• H. pylori revenue provides a commercial base, but chronic GERD prescriptions determine the franchise's long-term financial trajectory.
• Phathom's concentration in VOQUEZNA creates material upside from successful GERD adoption and material downside from reimbursement weakness or generic vonoprazan entry.
• Takeda's licensing economics reduce Phathom's retained product margin.
• The main near-term threat is substitution with generic components; the main long-term threat is a successful generic vonoprazan challenge.

FAQs About VOQUEZNA DUAL PAK

Is VOQUEZNA DUAL PAK the same as VOQUEZNA tablets?

No. VOQUEZNA DUAL PAK is a 14-day H. pylori eradication kit containing vonoprazan and amoxicillin. VOQUEZNA tablets are vonoprazan-only products approved for acid-related GERD indications.

Does VOQUEZNA DUAL PAK contain a proton-pump inhibitor?

No. Vonoprazan is a potassium-competitive acid blocker, not a conventional proton-pump inhibitor.

Can VOQUEZNA DUAL PAK be substituted with generic amoxicillin?

Amoxicillin is generic, but substituting individual products does not necessarily produce an FDA-approved equivalent to the branded Dual Pak regimen. Clinical and labeling considerations remain relevant.

Is VOQUEZNA DUAL PAK protected by orphan-drug exclusivity?

No. H. pylori infection is not an orphan indication, and the product's protection relies primarily on patents, regulatory approval and commercial execution.

What would most increase VOQUEZNA's valuation?

The largest valuation driver would be sustained prescription growth for VOQUEZNA tablets in erosive GERD, supported by favorable payer coverage and durable patent protection. Dual Pak growth alone would support the franchise but would not provide the same market scale.

References

1. U.S. Food and Drug Administration. (2022). VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). VOQUEZNA prescribing information. FDA.

3. Phathom Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

6. Phathom Pharmaceuticals, Inc. (2024). Full-year financial results and business update. Company investor-relations release.